Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Hospital employment models, reimbursement policies and private equity have all led to a massive reduction in the number of cardiologists working for a private practice, ACC President Cathie Biga, MSN, told Cardiovascular Business.
Alison Bailey, MD, co-chair of the business of cardiology sessions at ACC.24, emphasized that reimbursement cuts can have a long-term negative impact on patient.
All around the world, people are increasingly wise to the advance of AI. More than a few are growing ever more uneasy about it. And yet workers equipped with AI are both more productive and better at their jobs.
More than two-thirds of U.S. physicians have changed their minds about generative AI over the past year. In doing so, the re-thinkers have raised their level of trust in the technology to help improve healthcare.
A pharmacy benefit management company founded less than five years ago is teaming up with a drug pricing disrupter that will mark its second birthday next month.
Over the past three years, the value of claims waiting longer than 90 days for payment from commercial payers has risen by 33%. Stalled Medicare Advantage claims have spiked by even more.
In its annual outlook report released this week, Fitch Ratings says the coming calendar year will probably strike much of the sector as “another make or break” period.
Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.
Half a year after President Biden officially directed federal agencies in the executive branch’s bailiwick to “seize the promise and manage the risks” of AI, the White House has posted a status report.
U.S. physicians often receive payments from medical device manufacturers and pharmaceutical companies. New research in JAMA found a connection between receiving such payments and using specific devices—should the industry be concerned?